DeFrancesco Lisa 4

What Happened

• Lisa DeFrancesco, Senior Vice President, Investor Relations & Corporate Communications at Lexicon Pharmaceuticals (LXRX), had restricted stock units (RSUs) convert into 152,864 shares on February 28, 2026 (24,674 + 128,190). The company withheld 74,572 of those shares to cover tax withholding obligations at an indicated value of $1.47 per withheld share, totaling $109,621. After withholding, the net shares delivered to her were 78,292 (152,864 − 74,572).
• This was a routine equity award vesting/conversion and a tax-withholding transaction, not an open-market sale or purchase.

Key Details

• Transaction date: February 28, 2026; Form 4 filed March 3, 2026.
• Converted/issued: 152,864 shares (24,674 + 128,190); Withheld for taxes: 74,572 shares at $1.47/share = $109,621.
• Net shares received: 78,292 shares (noted above). The filing excerpt did not state total shares owned after the transaction.
• Relevant footnotes: F1/F3: each restricted stock unit equals one share; F2: shares were withheld by the company to satisfy tax withholding; F4: these RSUs vest 1/3 on Feb 28 of each of the three years after grant (vesting schedule).
• Transaction codes: M indicates conversion/exercise of a derivative (here, RSUs converting to shares); F indicates shares withheld to pay tax obligations.
• Filing timeliness: Form 4 filed March 3, 2026 covering Feb 28, 2026 transactions — no late filing flag shown in the report excerpt.

Context

• This appears to be a standard vesting/conversion of RSUs with a company share-withholding tax payment (a common “sell-to-cover” style action). Such transactions are routine compensation events and do not directly signal insider buying or selling intent in the open market.